Cabozantinib and Nivolumab in Treating Patients With Advanced, Recurrent or Metastatic Endometrial Cancer



Status:Recruiting
Healthy:No
Age Range:18 - Any
Updated:3/14/2019
Start Date:January 26, 2018
End Date:January 23, 2021

Use our guide to learn which trials are right for you!

A Randomized Phase 2 Study of Cabozantinib in Combination With Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer

This randomized phase II trial studies how well cabozantinib and nivolumab work in treating
patients with endometrial that has come back or spread to other places in the body.
Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth. Monoclonal antibodies, such as nivolumab, may interfere with the ability of
tumor cells to grow and spread. Giving cabozantinib and nivolumab may work better in treating
endometrial cancer.

PRIMARY OBJECTIVES:

I. To evaluate the clinical anti-tumor activity of XL184 (cabozantinib) and nivolumab based
on progression free survival (PFS) in patients with advanced, recurrent or metastatic
endometrial cancer previously treated with at least one line of platinum-based chemotherapy
compared to patients receiving nivolumab alone.

SECONDARY OBJECTIVES:

I. To evaluate the efficacy of XL184 and nivolumab in terms of overall response rate (ORR)
compared to nivolumab alone.

II. To evaluate overall survival (OS) of patients receiving XL184 and nivolumab compared to
patients receiving nivolumab alone.

III. To evaluate the safety of combination treatment using XL184 and nivolumab in patients
with advanced, recurrent metastatic endometrial cancer.

IV. To evaluate correlation between PD-L1 expression, CD3, CD4 and CD8 infiltrates and
outcome (PFS, ORR, OS).

V. To compare PD-L1 expression, CD3, CD4 and CD8 infiltrates in the primary tumor (archival
tissue) and in the tissue from baseline biopsy.

VI. To assess activity (PFS, ORR and OS) of nivolumab alone or in combination with XL184
according to microsatellite instability (MSI)/mismatched repair (MMR) status.

TERTIARY OBJECTIVES:

I. To assess activity (PFS, ORR and OS) of XL184 and nivolumab in patients progressed after
previous exposure to anti PD-1, PD-L1 or PD-L2 agents or crossed-over from single agent
nivolumab, and in patients with diagnosis of carcinosarcoma.

II. To compare microsatellite (MS) and MMR status, in the primary tumor (archival tissue) and
in the tissue from baseline biopsy.

III. To assess the genomic and immune-markers landscape at baseline on tumor tissue and
changes in immune landscape in peripheral blood during treatment and correlate with outcome.

OUTLINE: Patients are randomized to 1 of 2 arms.

Arm A: Patients receive cabozantinib orally (PO) once daily (QD) on days 1-28 and nivolumab
intravenously (IV) over 60 minutes on days 1 and 15, then on day 1 beginning course 5.

Arm B: Patients receive nivolumab as in Arm A. Patients may cross-over to Arm A at the time
of disease progression.

In both arms, courses repeat every 28 days in the absence of disease progression or
unacceptable toxicity.

After completion of study treatment, patients are followed up at 30-37 days, then every 12
weeks.

Inclusion Criteria:

- Patients must have histologically or cytologically confirmed epithelial endometrial
carcinoma; all histologies are accepted; patients with diagnosis of endometrial
carcinosarcoma will be enrolled in the exploratory cohort (arm C) and will receive
combination of cabozantinib and nivolumab

- Patients must have advance, recurrent or metastatic endometrial cancer

- Patients must have radiological evidence of disease progression following the most
recent treatment

- Patients must have measurable disease according Response Evaluation Criteria in Solid
Tumors (RECIST) version (v)1.1 criteria

- Must have MS/MMR result available at time of registration; MS/MMR status is to be
determined per local practice (i.e. immunohistochemistry [IHC], polymerase chain
reaction [PCR], or other methods)

- Prior therapy: eligible subjects must have had at least one line of platinum-based
chemotherapy; this may be adjuvant therapy or first line of cytotoxic therapy for
metastatic disease; prior hormonal therapy for metastatic/recurrent disease, prior
targeted therapy, and prior radiotherapy are allowed; no maximum number of previous
lines of chemotherapies; concomitant chemo-radiation is not considered as previous
line of systemic chemotherapy

- Availability of archival tissue for correlative analysis

- Eastern Cooperative Oncology Group (ECOG) performance status 0-2

- Absolute neutrophil count >= 1,500/mcL

- Platelets >= 100 x 10^9/L

- Total bilirubin =< 1.5 ULN (upper limit of normal), unless due to Gilbert's syndrome

- Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase
[SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
=< 3 × institutional upper limit of normal

- Creatinine =< 1.5 ULN OR creatinine clearance >= 50 mL/min/1.73 m^2 for patients with
creatinine levels above institutional normal

- Serum albumin > 28 g/L

- Lipase < 2 ULN

- Urine protein/ creatinine ratio (UPCR) =< 1

- Prothrombin time (PT)/ international normalized ratio (INR) and partial thromboplastin
time (PTT) test =< 1.3 ULN

- Patient must have disease amenable to biopsy and must agree to have one baseline
biopsy

- Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy
test at screening; WOCBP must agree to use adequate contraception (barrier method of
birth control or abstinence) prior to study entry and for the duration of study
participation; WOCBP should use an adequate method to avoid pregnancy for 7 months
after the last dose of investigational drug; women must not be breastfeeding; women of
childbearing potential (WOCBP) is defined as any female who has experienced menarche
and who has not undergone surgical sterilization (hysterectomy or bilateral
oophorectomy) or who is not postmenopausal; menopause is defined clinically as 12
months of amenorrhea in a woman over age 45 in the absence of other biological or
physiological causes; in addition, women under the age of 55 must have a documented
serum follicle stimulating hormone (FSH) level less than 40 mIU/mL; should a woman
become pregnant or suspect she is pregnant while she is participating in this study,
she should inform her treating physician immediately

- Ability to understand and the willingness to sign a written informed consent document

- CROSS-OVER ELIGIBILITY CRITERIA

- Patient must provide a tumor biopsy as the time of progression on Arm B; if a patient
does not have a tumor lesion amenable of biopsy or it has been unsafe for a biopsy to
be performed, cross-over will be allowed

Exclusion Criteria:

- Patients who have had chemotherapy (including investigational cytotoxic chemotherapy),
biologic agents (e.g. targeted therapy or antibodies) or radiotherapy within 4 weeks
prior to the first dose of study treatment

- Patients who have not recovered from adverse events attributed to prior anti-cancer
therapy (i.e. have residual toxicities > grade 1, except for alopecia, neuropathy,
lymphocytopenia and other non-clinically significant adverse events)

- Patients who are receiving any other investigational agents

- Patients should be excluded if they have had prior treatment with anti-CTLA-4 antibody
or any other antibody or drug specifically targeting T-cell co-stimulation; previous
treatment with anti-PD-1, anti-PD-L1 or anti-PD-L2 is allowed and patients will be
enrolled in the exploratory cohort (arm C) at the time of progression from last line
of treatment (treatment with immune check point inhibitor does not have to necessary
be the last line of treatment)

- Patients should be excluded if they have had prior treatment with cabozantinib;
previous use of other antiangiogenic agents other than cabozantinib is allowed

- Any other active malignancy other than the endometrial cancer, that is progressing or
requiring active treatment with the exception of basal or squamous cell skin cancer,
superficial bladder cancer, carcinoma in situ of any site

- Patients with known brain metastases should be excluded from this clinical trial

- Patients requiring concomitant treatment, in therapeutic doses, with anticoagulants
such as warfarin or warfarin-related agents, heparin, thrombin or factor Xa
inhibitors, antiplatelet agents (e.g. clopidogrel) or new oral anticoagulants;
low-dose aspirin (=< 81 mg/day), low-dose warfarin (=< 1 mg/day), and prophylactic low
molecular weight heparin (LMWH) are permitted

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to cabozantinib or nivolumab

- Patients require chronic concomitant treatment of strong CYP450 3A4 inducers (e.g.
dexamethasone, phenytoin, carbamazepine, rifampicin, rifabutin, rifapentine,
phenobarbital, St. John's wort) or inhibitors (eg. ketoconazole, miconazole,
itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, indinavir,
saquinavir, ritonavir, nelfinavir, amprenavir, fosamprenavir nefazodone, lopinavir,
troleandomycin, mibefradil and conivaptan)

- The subject has experienced any of the following:

- Clinically-significant gastrointestinal bleeding within 6 months before the first
dose of study treatment;

- Hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 3 months before the
first dose of study treatment;

- Any other signs indicative of hemorrhage within 3 months before the first dose of
study treatment

- The subject has radiographic evidence of cavitating pulmonary lesion(s)

- The subject has tumor invading or encasing any major blood vessels

- The subject has evidence of tumor invading the gastrointestinal (GI) tract (esophagus,
stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or
endobronchial tumor within 28 days before the first dose of XL184 (cabozantinib)

- Subject with extensive pelvic mass at risk of fistulization, or history of bowel
obstruction within 3 months prior to the proposed first dose of study treatment

- The subject has uncontrolled, significant intercurrent or recent illness including,
but not limited to, the following conditions:

- Cardiovascular disorders including:

- Congestive heart failure (CHF): New York Heart Association (NYHA) class III
(moderate) or class IV (severe) at the time of screening

- Concurrent uncontrolled hypertension defined as sustained blood pressure
(BP) > 140 mm Hg systolic, or > 90 mm Hg diastolic despite optimal
antihypertensive treatment within 7 days of the first dose of study
treatment

- Any history of congenital long QT syndrome

- Any of the following within 6 months before the first dose of study
treatment:

- Unstable angina pectoris

- Clinically-significant cardiac arrhythmias

- Stroke (including transient ischemic attack [TIA], or other ischemic
event)

- Myocardial infarction

- Thromboembolic event requiring therapeutic anticoagulation (Note:
subjects with a venous filter [e.g. vena cava filter] are not eligible
for this study)

- Gastrointestinal disorders particularly those associated with a high risk of
perforation or fistula formation including:

- Any of the following within 28 days before the first dose of study treatment

- Intra-abdominal tumor/metastases invading GI mucosa

- Active peptic ulcer disease,

- Inflammatory bowel disease (including ulcerative colitis and Crohn's
disease), diverticulitis, cholecystitis, symptomatic cholangitis or
appendicitis

- Malabsorption syndrome

- Any of the following within 6 months before the first dose of study
treatment:

- Abdominal fistula

- Gastrointestinal perforation

- Intra-abdominal abscess; Note: complete resolution of an
intra-abdominal abscess must be confirmed prior to initiating treatment
with cabozantinib even if the abscess occurred more than 6 months
before the first dose of study treatment

- Other disorders associated with a high risk of fistula formation including
percutaneous endoscopic gastrostomy (PEG) tube placement

- Other clinically significant disorders such as:

- Active infection requiring systemic treatment within 28 days before the first
dose of study treatment

- Serious non-healing wound/ulcer/bone fracture within 28 days before the first
dose of study treatment

- History of organ transplant

- Concurrent uncompensated hypothyroidism or thyroid dysfunction within 7 days
before the first dose of study treatment

- History of major surgery as follows:

- Major surgery within 3 months of the first dose of cabozantinib if there
were no wound healing complications or within 6 months of the first dose of
cabozantinib if there were wound complications

- Minor surgery within 1 month of the first dose of cabozantinib if there were
no wound healing complications or within 3 months of the first dose of
cabozantinib if there were wound complications

- In addition, complete wound healing from prior surgery must be confirmed at least
28 days before the first dose of cabozantinib irrespective of the time from
surgery

- Known active human immunodeficiency virus (HIV), acquired immunodeficiency syndrome
(AIDS) related illness, or hepatitis B or C infection

- Administration of a live vaccine within 4 weeks prior to start of protocol therapy

- Subjects with diagnosis of immunodeficiency or who are receiving systemic steroid
therapy or any other form of immunosuppressive therapy within 7 days prior to the
first dose of trial treatment; the following are exceptions to this exclusion
criteria: intranasal, inhaled, topical steroids, or local steroids injections (e.g.
intra-articular injection); systemic corticosteroids at physiologic dose not to exceed
10 mg/day of prednisone or equivalent; steroids as premedication for hypersensitivity
reactions (eg, computed tomography [CT] scan premedication)

- History of autoimmune disease, such as, but not restricted to: rheumatoid arthritis,
inflammatory bowel disease, systemic lupus erythematous, ankylosing spondylitis,
scleroderma, or multiple sclerosis requiring treatment within the last two years;
patients with vitiligo or diabetes are not excluded; replacement therapy (e.g.
thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or
pituitary insufficiency, etc.) is not considered a form of systemic treatment;
patients with recent history of thyroiditis; subjects with remote history (greater
than 5 years) of thyroiditis are not excluded

- Psychiatric illness/social situations that would limit compliance with study
requirements

- The subject has a corrected QT interval calculated by the Fridericia formula (QTcF) >
500 ms within 28 days before randomization; Note: if initial QTcF is found to be > 500
ms, two additional electrocardiogram (EKG)s separated by at least 3 minutes should be
performed; if the average of these three consecutive results for QTcF is =< 500 ms,
the subject meets eligibility in this regard

- Patient is not able to swallow pills

- Pregnant women are excluded from this study; breastfeeding should be discontinued if
the mother is treated with XL184 and nivolumab
We found this trial at
34
sites
Tampa, Florida 33612
Principal Investigator: Jing-Yi Chern
Phone: 800-456-7121
?
mi
from
Tampa, FL
Click here to add this to my saved trials
1300 Jefferson Park Avenue
Charlottesville, Virginia 22908
434-243-6784
Principal Investigator: Linda R. Duska
Phone: 434-243-6303
University of Virginia Cancer Center We are fortunate in having state of the art clinical...
?
mi
from
Charlottesville, VA
Click here to add this to my saved trials
1500 E Duarte Rd
Duarte, California 91010
(626) 256-4673
Principal Investigator: Daphne B. Stewart
Phone: 800-826-4673
City of Hope Comprehensive Cancer Center City of Hope is a leading research and treatment...
?
mi
from
Duarte, CA
Click here to add this to my saved trials
401 College Street
Richmond, Virginia 23298
(804) 828-0450
Principal Investigator: Sarah W. Gordon
Virginia Commonwealth University Massey Cancer Center Founded in 1974, VCU Massey Cancer Center is a...
?
mi
from
Richmond, VA
Click here to add this to my saved trials
401 North Broadway
Baltimore, Maryland 21287
410-955-5000
Principal Investigator: Stephanie L. Gaillard
Phone: 410-955-8804
Johns Hopkins University-Sidney Kimmel Cancer Center The name Johns Hopkins has become synonymous with excellence...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
450 Brookline Ave
Boston, Massachusetts 2215
617-632-3000
Principal Investigator: Panagiotis A. Konstantinopoulos
Phone: 877-442-3324
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
?
mi
from
Boston, MA
Click here to add this to my saved trials
5841 S Maryland Ave
Chicago, Illinois 60637
1-773-702-6180
Principal Investigator: Gini F. Fleming
Phone: 773-702-8222
University of Chicago Comprehensive Cancer Center The University of Chicago Comprehensive Cancer Center (UCCCC) is...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Principal Investigator: Daniela E. Matei
Phone: 312-695-1301
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: David M. O'Malley
Phone: 800-293-5066
?
mi
from
Columbus, OH
Click here to add this to my saved trials
10 Barnes West Drive
Creve Coeur, Missouri 63141
Principal Investigator: Premal H. Thaker
Phone: 800-600-3606
?
mi
from
Creve Coeur, MO
Click here to add this to my saved trials
5201 Harry Hines Blvd
Dallas, Texas 75235
(214) 590-8000
Principal Investigator: Jayanthi S. Lea
Phone: 214-590-5582
Parkland Memorial Hospital As our community's public health system, Parkland is the foundation for a...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Dallas, Texas 75390
Principal Investigator: Jayanthi S. Lea
Phone: 214-648-7097
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Fairway, Kansas 66205
Principal Investigator: Andrea D. Jewell
Phone: 913-945-7552
?
mi
from
Fairway, KS
Click here to add this to my saved trials
1600 Southwest Archer Road
Gainesville, Florida 32610
Principal Investigator: Merry J. Markham
Phone: 352-273-8010
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
3855 Health Sciences Dr,
La Jolla, California 92093
(858) 822-6100
Principal Investigator: Michael T. McHale
Phone: 858-822-5354
UC San Diego Moores Cancer Center Established in 1978, UC San Diego Moores Cancer Center...
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
1983 Marengo St
Los Angeles, California 90033
(323) 226-2622
Principal Investigator: Koji Matsuo
Phone: 323-865-0451
Los Angeles County-USC Medical Center The origins of LAC+USC Medical Center date back to 1878,...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
1441 Eastlake Ave
Los Angeles, California 90033
(323) 865-3000
Principal Investigator: Koji Matsuo
Phone: 323-865-0451
U.S.C./Norris Comprehensive Cancer Center The USC Norris Comprehensive Cancer Center, located in Los Angeles, is...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
600 Highland Ave
Madison, Wisconsin 53792
(608) 263-6400
Principal Investigator: Lisa M. Barroilhet
Phone: 800-622-8922
University of Wisconsin Hospital and Clinics UW Health strives to meet the health needs of...
?
mi
from
Madison, WI
Click here to add this to my saved trials
New Brunswick, New Jersey 08903
Principal Investigator: Eugenia Girda
Phone: 732-235-8675
?
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
New Lenox, Illinois 60451
Principal Investigator: Gini F. Fleming
Phone: 773-702-8222
?
mi
from
New Lenox, IL
Click here to add this to my saved trials
New York, New York 10016
Principal Investigator: Siobhan M. Kehoe
Phone: 212-263-4434
?
mi
from
New York, NY
Click here to add this to my saved trials
Orland Park, Illinois 60462
Principal Investigator: Gini F. Fleming
Phone: 773-702-8222
?
mi
from
Orland Park, IL
Click here to add this to my saved trials
111 S 11th St
Philadelphia, Pennsylvania 19107
(215) 955-6000
Principal Investigator: Christine H. Kim
Phone: 215-955-6084
Thomas Jefferson University Hospital Our hospitals in Center City Philadelphia share a 13-acre campus with...
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phoenix, Arizona
Principal Investigator: Matthew S. Block
Phone: 855-776-0015
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15232
Principal Investigator: Alexander B. Olawaiye
Phone: 412-647-8073
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Rochester, Minnesota 55905
Principal Investigator: Matthew S. Block
Phone: 855-776-0015
?
mi
from
Rochester, MN
Click here to add this to my saved trials
Sacramento, California 95817
Principal Investigator: Vanessa A. Kennedy
Phone: 916-734-3089
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
Saint Louis, Missouri 63129
Principal Investigator: Premal H. Thaker
Phone: 800-600-3606
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
11155 Dunn Road
Saint Louis, Missouri 63136
Principal Investigator: Premal H. Thaker
Phone: 800-600-3606
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Principal Investigator: Premal H. Thaker
Phone: 800-600-3606
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
150 Entranceway Drive
Saint Peters, Missouri 63376
Principal Investigator: Premal H. Thaker
Phone: 800-600-3606
?
mi
from
Saint Peters, MO
Click here to add this to my saved trials
2000 Circle of Hope Dr
Salt Lake City, Utah 84112
(801) 585-0303
Principal Investigator: Theresa L. Werner
Phone: 888-424-2100
Huntsman Cancer Institute at University of Utah Huntsman Cancer Institute (HCI) is part of the...
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
13400 E. Shea Blvd.
Scottsdale, Arizona 85259
480-301-8000
Principal Investigator: Matthew S. Block
Phone: 855-776-0015
Mayo Clinic Arizona Mayo Clinic in Arizona provides medical care for thousands of people from...
?
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Toronto, Ontario
Principal Investigator: Stephanie Lheureux
Phone: 416-946-4501
?
mi
from
Toronto,
Click here to add this to my saved trials